Perrigo Co PLC Faces Surge of Investor Litigation Amid Market Volatility

Perrigo Co PLC (NYSE: PRGO), the global manufacturer of over‑the‑counter health‑care products, infant formulas and generic pharmaceuticals, has become the focal point of a growing investor‑rights movement. Over the past week, three major law firms—Levi & Korsinsky, Rosen Law Firm, and Robbins LLP—have announced securities class‑action lawsuits alleging that the company’s disclosures and trading practices have misled shareholders, potentially causing substantial losses.

  • Levi & Korsinsky, LLP filed a securities class‑action suit on behalf of investors who bought or otherwise acquired PRGO securities, emphasizing the January 16, 2026 lead‑plaintiff deadline. The firm’s communications urge investors who suffered losses to “learn about Perrigo Company plc Class Action” and to contact Joseph E. Lev for counsel.
  • Rosen Law Firm, PA highlighted that the class period spans from February 27, 2023 to November 4, 2025. The firm’s outreach underscores the importance of the January 16 deadline and invites investors to seek representation to recover potential damages without a traditional settlement.
  • Robbins LLP joined the chorus, reminding shareholders that losses incurred during the class period may qualify for compensation under federal securities laws.

The lawsuits claim that PRGO failed to disclose material information affecting its valuation, thereby inducing a mispricing that has eroded investor confidence. While the specific allegations remain unsubstantiated pending litigation, the coordinated legal campaigns have already amplified scrutiny of the company’s corporate governance and disclosure practices.

Market Response

Perrigo’s share price, which closed at €11.205 on 18 December 2025, sits well below its 52‑week low of €10.505 (20 November 2025) and more than one third of its 52‑week high of €29.31 (2 March 2025). The company’s market capitalization, approximately €1.56 billion, reflects a valuation that investors are now questioning in light of the pending litigation.

The price‑to‑earnings ratio of 8.15 suggests that the market still views Perrigo’s earnings potential favorably, but the recent legal developments have introduced additional risk premiums. Analysts are monitoring whether the court’s decisions will prompt regulatory review or compel the company to restructure its investor‑relations strategy.

Forward‑Looking Outlook

Despite the current legal turbulence, Perrigo’s core business remains robust. The company’s diversified portfolio of OTC health‑care products and generic pharmaceuticals positions it well to weather market cycles. However, the litigation may:

  1. Elevate Compliance Costs – Additional regulatory scrutiny could drive up legal and reporting expenses.
  2. Impact Capital Access – Potential liabilities might constrain future equity or debt financing.
  3. Alter Investor Perception – Persistent negative media coverage could depress long‑term valuation.

Proactive engagement with shareholders, transparent disclosure of pending proceedings, and a clear remediation plan may mitigate reputational damage. Investors who hold PRGO securities should evaluate their positions relative to the class‑action timeline and consider whether participation could yield restitution.

In sum, Perrigo Co PLC is navigating a confluence of legal challenges and market volatility. The outcomes of the forthcoming litigation will likely shape the company’s strategic trajectory and its relationship with the investment community for months to come.